Amphora Discovery is a leading provider of integrated services for the pharmaceutical industry. We employ cutting-edge chemogenomic, systems biology and microfluidics technologies to deliver innovative and targeted lead generation and lead optimization solutions for our customers. Our mission is to enhance and improve the efficiency of our clients’ discovery efforts through a process that shortens traditional timelines.
The Company, headquartered in Research Triangle Park, North Carolina, USA, began operations in early 2002. Since our inception, we have built a cutting-edge drug discovery platform based on high precision microfluidic technology that delivers on the promise of shortening and improving lead generation and lead optimization processes. Our state-of-the-art research facility (shown below) has a flexible capacity to screen 1 million wells per week in an efficient, validated and automated process. This platform is built on quality principles that employ validated and optimized processes to provide extremely high quality data and thereby reduce timelines and costs.
Amphora Discovery has been a pioneer in the adoption and commercialization of microfluidic assay technology. The Company’s founders were early-access partners involved with development of Caliper Life Sciences’ microfluidics screening system and are the foremost authorities on its use in drug discovery. We have performed more than 100 high throughput screening campaigns and generated over 35 million data points with our discovery platform.
Our products and services include in vitro assay protocols, optimized in vitro high throughput screening and compound profiling services, custom assay development, expert enzymology services and lead discovery/lead optimization partnering programs. Our clients include major pharmaceutical and biopharmaceutical companies, emerging biotechnology companies and major research foundations worldwide.